Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
| Project/Area Number |
15K18939
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Osaka Ohtani University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 糖尿病 / アデノウイルスベクター / GWAS / 遺伝子治療 / MAEA / 糖代謝 / 生活習慣病 / 肝臓 / 改良型アデノウイルスベクター |
|---|
| Outline of Final Research Achievements |
In order to determine a new treatment option for type 2 diabetes mellitus, this study focused on the macrophage erythroblast attacher (MAEA), a type 2 diabetes mellitus susceptibility gene identified via genome-wide association study (GWAS). MAEA encodes a protein involved in the terminal maturation and enucleation of erythroid cells; however, no association with type 2 diabetes mellitus has been reported and clarification of its functions is still awaited. Therefore, to investigate its effect on type 2 diabetes mellitus, MAEA was highly expressed in mouse and mouse primary hepatocytes using a novel adenovirus vector suitable as a gene therapy vector for metabolic diseases. Expression of the gluconeogenesis gene was suppressed by highly expressing MAEA. The results suggest that MAEA may lead to a new type of treatment for type 2 diabetes mellitus by suppressing gluconeogenesis.
|
Report
(4 results)
Research Products
(25 results)
